Following backlash after it initially refused to review Moderna’s mRNA influenza vaccine, the US Food and Drug Administration (FDA) will now review the vaccine.
Moderna submitted an application for the FDA to approve the new product in December 2025. Other countries, including Australia, accepted the vaccine for review. The FDA’s initial refusal to review the vaccine sparked concerns about the influence of the current administration.
Read the full article at The Guardian: FDA reverses course and will review Moderna’s mRNA-based flu vaccine.